Neovascular age related macular degeneration

Results 191 to 200 of about 31,226 (229)

Some of the next articles are maybe not open access.

Innovative therapies for neovascular age-related macular degeneration

Expert Opinion on Pharmacotherapy, 2019
Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies.
Hasenin, Al-Khersan +3 more
openaire +2 more sources

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Immunotherapy, 2013
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in patients over the age of 50 in the western world. Intravitreally administered anti-VEGF drugs have been developed to halt neovascular growth in AMD. Randomized trials have demonstrated the excellent safety profile and significant benefit of anti-VEGF therapy ...
David, Xu, Peter K, Kaiser
openaire +2 more sources

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Lancet, The, 2022
Jeffrey S Heier, Arshad M Khanani, Frank G Holz +2 more
exaly

Age-related macular degeneration

Lancet, The, 2023
Robyn H. Guymer
exaly

Neovascular age-related macular degeneration